DanDrit® Biotech A/S is a clinical-stage company committed to developing the world's first vaccine against colorectal cancer. DanDrit is one of the world’s leaders when it comes to development of dendritic cell vaccines. DanDrit's lead compound, MelCancerVac® (MCV), an allogenic dendritic cell vaccine, has successfully completed two Phase II clinical trials for the treatment of advanced colorectal cancer and non-small cell lung cancer (NSCLC). DanDrit now takes MCV into an international multicenter double-blind comparative Phase IIb / III clinical trial with 174 advanced colorectal cancer patients.
DanDrit Corporation Pte Ltd in Singapore is a 100% owned subsidiary of DanDrit Biotech A/S.